6 November 2026
originally posted on LinkedIn.
Africa’s drive to strengthen its pharmaceutical manufacturing is no longer just an ambition: it is gaining tangible traction. Across the continent, investments, licensing agreements, technology transfer initiatives and partnerships are creating new opportunities to expand local production of medicines, vaccines, diagnostics and other health products.
This progress is encouraging. Yet, as I reflected during the AHMTEC | African Healthcare Manufacturing Trade Exhibition and Conference (AHMTEC) 2026 in Addis Ababa, a critical question remains: How do we ensure that partnership commitments translate into sustained manufacturing and improved access to health products?
I had the opportunity to participate in the panel discussion “Partner to Perform – Building Successful Partnerships for Healthcare Manufacturing in Africa”, which explored the factors that make partnerships successful, the challenges in implementation and the lessons we can draw from practical experience. The discussion was moderated by Mariatou Tala Jallow, Director of the African Pooled Procurement Mechanism (APPM) at Africa CDC, and included insightful contributions from fellow panelists Assietou Sylla Diouf, CEO of VaxSen, and Robert Lloyd, Associate Vice President for Social Impact at Eli Lilly.
Drawing on Medicines Patent Pool (MPP’s) experience, I highlighted four key considerations for manufacturers seeking to structure agreements that can translate into successful implementation and sustainable outcomes:
1. Choosing the right product and the right time
At MPP, we have seen the importance of looking beyond today’s market when assessing licensing and technology transfer opportunities.
Manufacturers need to anticipate future health needs, changes in treatment guidelines and emerging technologies. A product that looks commercially attractive today may be overtaken by a newer treatment tomorrow.
Timing matters just as much. In HIV, some licences concluded by MPP and its partners convered products that had only recently received regulatory approval, such as dolutegravir, or had not yet been approved, such as tenofovir alafenamide(TAF). This gave generic manufacturers opportunities to begin development earlier and prepare the future demand.
More recently, MPP’s agreement with Roche for baloxavir marboxil illustrates the value of establishing manufacturing pathways ahead of a potential influenza emergency. Early engagement, however, is not without risk: demand may fall short of expectations, and investments may take time to generate returns. The opportunity for an early-mover advantage must therefore be weighed against these uncertainties.
2. Making technology transfer deliver in practice
Technology transfer is sometimes treated as a single transaction. In practice, it is a complex process requiring sustained technical engagement, investment and commitment from both parties. Agreements should specify what innovators will transfer, including technical know-how, documentation, materials and training and the technical assistance that will accompany the transfer.
MPP’s agreement with SD Biosensor under the World Health Organization (WHO) Health Technology Access Pool (HTAP), covering rapid diagnostic testing technology, offers a practical example. Beyond intellectual property rights, the agreement provides the transfer of know-how and materials, as well as technical assistance.
The essential point is that both parties should have a clear, shared understanding of the scope of the transfer, the support available and their respective responsibilities.
3. Assessing readiness and planning a phased path to production
Manufacturers enter partnerships with different levels of technical capacity, infrastructure and experience. Not every manufacturer can undertake every stage of production from the outset. Baseline assessments help establish existing capabilities, identify gaps in infrastructure, equipment, workforce skills and quality systems, and determine the support and investment needed to build manufacturing readiness.
The WHO-MPP mRNA Technology Transfer Programme illustrates why readiness assessments and peer learning matter. The programme brings together 16 manufacturing partners across 15 low- and middle-income countries, including six in Africa, to build mRNA capabilities through technology transfer, training and collaboration. This network creates opportunities for manufacturers to learn from one another while developing capabilities suited to their starting points. Not all partners will reach full-scale production at the same pace; progress needs to be assessed against realistic, staged milestones.
Another example is MPP’s sublicence agreement with Codix Bio Ltd in Nigeria for SD BIOSENSOR INC ’s rapid diagnostic test technology (RDT). It envisages three phases of implementation: starting with the supply of packaged test components, progressing to semi-finished products and ultimately enabling more extensive local manufacturing.
For manufacturers, the lesson is to agree on realistic milestones, clear criteria for moving between phases and practical mechanisms to monitor progress and address delays or capability gaps.
4. Ensuring that agreements support commercial viability
The ability to manufacture a product does not guarantee commercially sustainable supply. Manufacturers must also assess whether the terms of an agreement provide a credible route to a viable operation. Important considerations include the geographical scope of the licence, flexibility to source active pharmaceutical ingredients (APIs) and other inputs, opportunities to collaborate with other partners, royalties and other financial obligations, regulatory requirements and routes to market.
These terms must be assessed alongside investment needs, expected production costs, market size, competition and the outlook for demand. The ability to manufacture a product is only part of the equation. Equally important is ensuring that it can be supplied sustainably, and successful partnerships must address both.
In conclusion, partnerships need to be designed for results beyond the signing ceremony. That means selecting appropriate technologies, setting realistic commitments, building capabilities progressively and creating the market conditions manufacturers need to succeed. It also means agreeing from the outset how success will be defined and measured—not only through agreements signed, but through capabilities developed, manufacturing milestones achieved, products registered, markets reached and, above all, people who gain access to needed health products.
MPP’s experience offers a reminder of what sustained partnerships can achieve. Through partnerships with 23 innovators MPP has helped enable generic manufacturers and product developers to deliver more than 60 billion doses of treatments across 148 countries, generating billions of US dollars in estimated savings through lower prices and contributing to thousands of lives saved.
I left AHMTEC encouraged by the growing recognition that advancing pharmaceutical manufacturing in Africa requires collective effort, and by the determination of African manufacturers and partners to translate this ambition into tangible results. Ultimately, the success of these partnerships will be measured not by the number of agreements concluded, but by their contribution to sustainable manufacturing and improved access to quality-assured health products.
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of innovative medicines and other health technologies for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed health products and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 23 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, one antiviral treatment for influenza, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada and Coeffient Giving. MPP’s activities in technology transfer are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, the Government of Flanders and SDC.